naltrexone has been researched along with oxymorphone in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (49.09) | 18.7374 |
| 1990's | 9 (16.36) | 18.2507 |
| 2000's | 7 (12.73) | 29.6817 |
| 2010's | 11 (20.00) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Berkowitz, DS; Loew, GH | 1 |
| Klein, P; Nelson, WL | 1 |
| Archer, S; Corbett, AD; Kosterlitz, HW; McKnight, AT; Paterson, SJ; Seyed-Mozaffari, A; Ward, S | 1 |
| Lipkowski, AW; Portoghese, PS; Tam, SW | 1 |
| Hahn, EF; Pasternak, GW | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Ferguson, DM; Metzger, TG; Paterlini, MG; Portoghese, PS | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fujii, H; Hasebe, K; Izumimoto, N; Mochizuki, H; Momen, S; Nagase, H; Nakajima, R; Nemoto, T; Yamamoto, N | 1 |
| Burgman, M; Grinnell, S; Haselton, N; Le Rouzic, V; Majumdar, S; Nagakura, K; Ocampo, J; Pan, YX; Pasternak, AR; Pasternak, GW; Polikar, L; Subrath, J | 1 |
| England, PM; Harvey, JH; Long, DH; Whistler, JL | 1 |
| Coop, A; Cunningham, CW; Eddington, ND; Hassan, HE; Mercer, SL; Metcalf, MD; Rosicky, AD | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brockmöller, J; Friesacher, HR; Meyer, MJ; Neumann, VE; Tzvetkov, MV; Zdrazil, B | 1 |
| Fishman, J; Foldes, FF; Hahn, EF; Ronai, AZ | 1 |
| Caruso, TP; Larson, DL; Portoghese, PS; Takemori, AE | 2 |
| Bykov, V; Holaday, JW; Jacobson, AE; Long, JB; Rice, KC; Rothman, RB | 1 |
| Leander, JD; Mayer-Valkanover, K; Nussbaumer, C; Schmidhammer, H; Schmidt, C; Schoepp, DD; Schratz, A; Walla-Kugler, M | 1 |
| Angel, L; Appelmans, N; Gioannini, TL; Koolpe, GA; Nelson, WL; Simon, EJ | 1 |
| Goodman, RR; Hahn, EF; Nishimura, S; Pasternak, GW | 1 |
| Einarsson, M; Koman, A; Terenius, L | 1 |
| Galetta, S; Hahn, EF; Nishimura, S; Pasternak, GW | 1 |
| Botros, S; Larson, DL; Lipkowski, AW; Portoghese, PS; Stark, PA; Takemori, AE | 1 |
| Belluzzi, JD; Stein, L; Trujillo, KA | 1 |
| Abdelhamid, EM; Archer, S; Koolpe, GA; Michael, J; Michael, M; Nelson, WL; Simon, EJ | 1 |
| Cho, TM; Nozaki, M | 1 |
| Larson, DL; Lipkowski, AW; Portoghese, PS; Rice, KC; Ronsisvalle, G; Sayre, LM; Takemori, AE; Tam, SW; Yim, CB | 1 |
| Jacobson, AE; Rice, KC; Sadée, W; Yu, VC | 1 |
| Armstrong, MJ; Larson, AA | 1 |
| Carroll-Buatti, M; Hahn, EF; Pasternak, GW | 1 |
| Giles, T; Merz, H; Sander, G | 1 |
| France, CP; Jacobson, AE; Woods, JH | 2 |
| Angel, L; Gioannini, TL; Koolpe, GA; Nelson, WL; Simon, EJ | 1 |
| Fries, DS; Larson, DL; Portoghese, PS; Sayre, LM; Takemori, AE | 1 |
| Larson, DL; Portoghese, PS; Takemori, AE | 1 |
| Pasternak, GW | 1 |
| Bowen, WD; Pert, CB; Rothman, RB; Schumacher, UK | 1 |
| Gao, P | 1 |
| DiGiacomo, B; Larson, DL; Ohkawa, S; Portoghese, PS; Takemori, AE | 1 |
| Fang, X; Larson, DL; Portoghese, PS | 1 |
| Fang, X; Kshirsagar, TA; Portoghese, PS | 1 |
| Gao, P; Larson, DL; Portoghese, PS | 1 |
| Borsodi, A; Hosztafi, S; Nevin, ST; Rónai, AZ; Spetea, M; Tóth, G | 1 |
| Jones, RM; McCurdy, CR; Portoghese, PS | 1 |
| Adams, M; Ahdieh, H; Gammaitoni, AR; Pieniaszek, HJ | 1 |
| Daniels, DJ; Lenard, NR; Portoghese, PS; Roerig, SC | 1 |
| Crawford, D; Lasukova, TV; Lishmanov, AY; Maslov, LN; Wong, TM | 1 |
| Virk, MS; Williams, JT | 1 |
| Al-Khrasani, M; Asim, MF; Friedmann, T; Furst, S; Király, KP; Riba, P; Schmidhammer, H; Sobor, M; Spetea, M | 1 |
| Pappagallo, M; Sokolowska, M | 1 |
| Hosztafi, S; Mazák, K; Noszál, B | 1 |
| Ahrens, B; Kucherova, Y; Sobolevsky, T | 1 |
| Cunningham, CW; France, CP; Gerak, LR; Hu, Z; Mada, S; Maguire, DR; Minervini, V; Soyer, A | 1 |
2 review(s) available for naltrexone and oxymorphone
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for naltrexone and oxymorphone
| Article | Year |
|---|---|
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.
Topics: Adolescent; Adult; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam; Middle Aged; Naltrexone; Oxymorphone; Rifampin; Tolbutamide | 2005 |
52 other study(ies) available for naltrexone and oxymorphone
| Article | Year |
|---|---|
Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.
Topics: Analgesics, Opioid; Animals; Hydromorphone; In Vitro Techniques; Mice; Molecular Conformation; Oxymorphone; Quantum Theory; Rats; Structure-Activity Relationship; Swine; Thermodynamics | 1978 |
O3-(2-carbomethoxyallyl) ethers of opioid ligands derived from oxymorphone, naltrexone, etorphine, diprenorphine, norbinaltorphimine, and naltrindole. Unexpected O3-dealkylation in the opioid radioligand displacement assay.
Topics: Alkylation; Animals; Brain; Diprenorphine; Drug Stability; Ethers; Etorphine; Guinea Pigs; Indoles; Methacrylates; Molecular Structure; Morphinans; Naltrexone; Narcotic Antagonists; Narcotics; Oxymorphone; Phenols; Radioligand Assay; Receptors, Opioid; Tritium | 1992 |
10-Ketonaltrexone and 10-ketooxymorphone.
Topics: Animals; Biological Assay; Brain; Chemical Phenomena; Chemistry; Guinea Pigs; Hydromorphone; Ileum; Male; Mice; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Structure-Activity Relationship; Vas Deferens | 1985 |
Peptides as receptor selectivity modulators of opiate pharmacophores.
Topics: Animals; Dynorphins; Endorphins; Enkephalin, Leucine; Guinea Pigs; Indicators and Reagents; Kinetics; Oligopeptides; Receptors, Opioid; Structure-Activity Relationship | 1986 |
Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.
Topics: Analgesics, Opioid; Animals; Brain; Delayed-Action Preparations; Hydrazones; Hydromorphone; In Vitro Techniques; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Oxymorphone; Rats; Receptors, Opioid | 1980 |
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Topics: Amino Acid Sequence; Base Sequence; Binding, Competitive; Cell Line; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Oxymorphone; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2001 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.
Topics: Analgesics, Opioid; Animals; Bridged-Ring Compounds; Cells, Cultured; Mice; Molecular Structure; Protein Binding; Receptors, Opioid, kappa; Structure-Activity Relationship; Substrate Specificity | 2011 |
Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.
Topics: Amides; Analgesics; Animals; Behavior, Animal; Brain; Cell Line; Chemistry Techniques, Synthetic; Exons; Male; Mice; Opiate Alkaloids; Protein Isoforms; Protein Structure, Tertiary; Receptors, Opioid, mu; Structure-Activity Relationship | 2012 |
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.
Topics: | 2012 |
Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Conformation; Morphinans; Structure-Activity Relationship | 2014 |
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
Topics: Analgesics, Opioid; HEK293 Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Organic Cation Transporter 1; Permeability; Protein Conformation | 2019 |
Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series.
Topics: Animals; Guinea Pigs; Hydromorphone; Male; Naloxone; Naltrexone; Narcotic Antagonists; Oxygen; Oxymorphone; Structure-Activity Relationship | 1977 |
Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
Topics: Alkylating Agents; Animals; Chlorambucil; Dose-Response Relationship, Drug; Drug Synergism; Guinea Pigs; Hydromorphone; In Vitro Techniques; Morphine; Naloxone; Naltrexone; Nitrogen Mustard Compounds; Norepinephrine; Oxymorphone; Phenoxybenzamine; Receptors, Opioid | 1979 |
Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
Topics: Animals; Brain; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; In Vitro Techniques; Isothiocyanates; Kinetics; Naltrexone; Narcotic Antagonists; Oxymorphone; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu; Thiocyanates; Up-Regulation | 1990 |
5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
Topics: Animals; Ethers; In Vitro Techniques; Methylation; Naloxone; Naltrexone; Narcotic Antagonists; Oxymorphone; Quaternary Ammonium Compounds; Receptors, Opioid; Structure-Activity Relationship | 1990 |
Opioid agonists and antagonists. 6-Desoxy-6-substituted lactone, epoxide, and glycidate ester derivatives of naltrexone and oxymorphone.
Topics: Animals; Binding, Competitive; Brain; Chemical Phenomena; Chemistry; Circular Dichroism; Epoxy Compounds; Ethers, Cyclic; Hydromorphone; Lactones; Male; Naloxone; Naltrexone; Oxymorphone; Propionates; Rats; Rats, Inbred Strains; Receptors, Opioid; Structure-Activity Relationship | 1985 |
Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
Topics: Animals; Binding, Competitive; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Hydromorphone; In Vitro Techniques; Male; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Oxymorphone; Rats; Rats, Inbred Strains; Receptors, Opioid; Structure-Activity Relationship | 1985 |
Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation.
Topics: Animals; Chemical Phenomena; Chemistry; Depression, Chemical; Fluorescent Dyes; Guinea Pigs; Hydromorphone; Ileum; In Vitro Techniques; Male; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Stereoisomerism; Stimulation, Chemical | 1985 |
Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
Topics: Analgesia; Animals; Binding, Competitive; Brain; Dihydromorphine; Endorphins; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Hydromorphone; Male; Mice; Mice, Inbred ICR; Naltrexone; Oxymorphone; Rats; Rats, Inbred Strains; Receptors, Opioid; Sodium | 1987 |
Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
Topics: Animals; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Guinea Pigs; Hydromorphone; Male; Mice; Muscle, Smooth; Naltrexone; Narcotic Antagonists; Oxymorphone; Pain; Structure-Activity Relationship | 1989 |
Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation.
Topics: Animals; Brain Mapping; Male; Motivation; Naloxone; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Oxymorphone; Quaternary Ammonium Compounds; Rats; Rats, Inbred Strains; Receptors, Opioid; Self Stimulation; Septal Nuclei | 1989 |
Chloroacryloyl amides and alpha-methylenelactones from naltrexone, oxymorphone and fentanyl.
Topics: Acrylates; Animals; Binding Sites; Brain; Chemical Phenomena; Chemistry; Fentanyl; Hydromorphone; In Vitro Techniques; Membranes; Naloxone; Naltrexone; Oxymorphone; Rats; Stereoisomerism | 1985 |
Effects of 5,5'-dithiobis-(2-nitrobenzoic acid) on opiate binding to both the membrane-bound receptor and the partially purified opiate receptor.
Topics: Animals; Butorphanol; Cell Membrane; Dihydromorphine; Diprenorphine; Dithionitrobenzoic Acid; Dithiothreitol; Etorphine; Morphine; Nalorphine; Naloxone; Naltrexone; Nitrobenzoates; Oxymorphone; Rats; Receptors, Opioid | 1985 |
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors.
Topics: Animals; Brain; Chemical Phenomena; Chemistry; Endorphins; Guinea Pigs; Ileum; Naltrexone; Oxymorphone; Receptors, Opioid; Stereoisomerism; Structure-Activity Relationship | 1985 |
Stereospecificity of 4,5-epoxymorphinan binding to the lambda site in rat brain.
Topics: Animals; Binding, Competitive; Brain; In Vitro Techniques; Male; Morphinans; Morphine; Naloxone; Naltrexone; Narcotics; Oxymorphone; Rats; Rats, Inbred Strains; Receptors, Opioid; Stereoisomerism | 1984 |
Morphine analgesia after intrathecal administration of a narcotic agonist, chloroxymorphamine and antagonist, chlornaltrexamine.
Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Drug Interactions; Hydromorphone; Injections, Spinal; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Nitrogen Mustard Compounds; Oxymorphone; Rats | 1980 |
Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
Topics: Analgesics; Animals; Brain; Hydromorphone; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Nitrogen Mustard Compounds; Oxymorphone | 1980 |
Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
Topics: Animals; Brain; Cell Membrane; Dihydromorphine; Drug Stability; Hydromorphone; Kinetics; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Structure-Activity Relationship | 1982 |
Quaternary opiate antagonists lower blood pressure and inhibit leucine-enkephalin responses.
Topics: Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Enkephalin, Leucine; Heart Rate; Hydromorphone; Naloxone; Naltrexone; Oxymorphone; Quaternary Ammonium Compounds | 1983 |
Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine.
Topics: Animals; Buprenorphine; Columbidae; Discrimination Learning; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Hydromorphone; Morphinans; Morphine; Naltrexone; Oxymorphone; Time Factors | 1984 |
Irreversible and reversible narcotic agonists: discriminative and analgesic effects of buprenorphine, oxymorphazone, and morphine.
Topics: Animals; Buprenorphine; Columbidae; Discrimination Learning; Dose-Response Relationship, Drug; Hydromorphone; Mice; Morphinans; Morphine; Naltrexone; Nociceptors; Oxymorphone | 1984 |
Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor liga
Topics: Animals; Brain; Cell Membrane; Chromatography, Thin Layer; Hydromorphone; Indicators and Reagents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Conformation; Naloxone; Naltrexone; Narcotic Antagonists; Optical Rotation; Oxymorphone; Rats; Rats, Inbred Strains; Receptors, Opioid; Structure-Activity Relationship | 1984 |
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.
Topics: Alkylating Agents; Animals; Guinea Pigs; In Vitro Techniques; Morphinans; Muscle Contraction; Muscle, Smooth; Naltrexone; Narcotic Antagonists; Narcotics; Oxymorphone; Receptors, Opioid | 1980 |
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
Topics: Affinity Labels; Animals; Ileum; Male; Mice; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Structure-Activity Relationship | 1981 |
Opiate, enkephalin, and endorphin analgesia: relations to a single subpopulation of opiate receptors.
Topics: Analgesia; Animals; Humans; Lethal Dose 50; Morphine; Muridae; Naloxone; Naltrexone; Oxymorphone; Receptors, Opioid; Respiration; Respiratory Insufficiency | 1981 |
Effect of beta-FNA on opiate receptor binding: preliminary evidence for two types of mu receptors.
Topics: Animals; Brain; In Vitro Techniques; Naloxone; Naltrexone; Oxymorphone; Rats; Receptors, Opioid; Receptors, Opioid, mu | 1983 |
Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study.
Topics: Drug Design; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Naltrexone; Narcotic Antagonists; Oxymorphone; Peptides, Cyclic; Protein Binding; Protein Conformation; Receptors, Opioid, delta; Spiro Compounds; Structure-Activity Relationship | 1996 |
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
Topics: Analgesia; Analgesics; Animals; Brain; Cell Membrane; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Guinea Pigs; Ileum; Ligands; Male; Mice; Mice, Inbred ICR; Molecular Structure; Muscle, Smooth; Naltrexone; Oxymorphone; Receptors, Opioid, delta; Spiro Compounds; Vas Deferens | 1997 |
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
Topics: Animals; Electric Stimulation; Guinea Pigs; Hydromorphone; In Vitro Techniques; Ligands; Male; Mice; Molecular Conformation; Molecular Structure; Muscle Contraction; Muscle, Smooth; Naltrexone; Narcotics; Oxymorphone; Receptors, Opioid, delta; Spiro Compounds; Structure-Activity Relationship | 1997 |
14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
Topics: Animals; Guinea Pigs; Ileum; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Naltrexone; Narcotic Antagonists; Oxymorphone; Receptors, Opioid, delta; Spiro Compounds; Vas Deferens | 1998 |
Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
Topics: Animals; Electric Stimulation; Guinea Pigs; Ileum; In Vitro Techniques; Ligands; Male; Mice; Models, Molecular; Molecular Conformation; Morphinans; Muscle, Smooth; Naltrexone; Narcotic Antagonists; Oxymorphone; Pain Measurement; Receptors, Opioid, delta; Spiro Compounds; Vas Deferens | 1998 |
Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids.
Topics: Animals; Benzeneacetamides; Benzofurans; Binding, Competitive; Brain; Cell Membrane; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Naloxone; Naltrexone; Oligopeptides; Oxycodone; Oxymorphone; Pyrrolidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu; Tritium | 1998 |
Investigation of phenolic bioisosterism in opiates: 3-sulfonamido analogues of naltrexone and oxymorphone.
Topics: Indicators and Reagents; Models, Molecular; Molecular Conformation; Naltrexone; Narcotics; Oxymorphone; Stereoisomerism; Sulfonamides | 2000 |
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Psychological; Ligands; Male; Mice; Mice, Inbred ICR; Morphine; Naltrexone; Narcotic Antagonists; Oxymorphone; Pain; Receptors, Opioid, delta; Receptors, Opioid, mu | 2007 |
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzophenanthridines; Glyburide; Male; Myocardial Reperfusion Injury; Naltrexone; Oxymorphone; Potassium Channels; Protein Kinase C; Rats; Rats, Wistar; Receptors, Opioid, kappa | 2007 |
Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization.
Topics: Analgesics, Opioid; Animals; Down-Regulation; Electrophysiology; Enkephalins; Etorphine; Fentanyl; In Vitro Techniques; Male; Naltrexone; Oxymorphone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu | 2008 |
Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Topics: Analgesics, Opioid; Animals; Brain; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Male; Mice; Mice, Inbred Strains; Models, Biological; Morphine; Morphine Derivatives; Naltrexone; Oxymorphone; Pain; Rats; Rats, Wistar; Receptors, Opioid, mu; Vas Deferens | 2010 |
The implications of tamper-resistant formulations for opioid rotation.
Topics: Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Drug Tolerance; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone; Oxymorphone; Patient Selection | 2012 |
Species-specific lipophilicity of morphine antagonists.
Topics: 1-Octanol; Hydrogen-Ion Concentration; Naloxone; Naltrexone; Narcotic Antagonists; Oxymorphone; Potentiometry; Water | 2015 |
Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone.
Topics: Doping in Sports; Drug Stability; Gas Chromatography-Mass Spectrometry; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Oxymorphone; Quaternary Ammonium Compounds; Substance Abuse Detection | 2018 |
Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Male; Morphine; Naltrexone; Narcotic Antagonists; Oxymorphone; Pain; Pain Measurement; Rats; Receptors, Opioid, delta; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration | 2020 |